Toast, Inc. Class A TOST 深 沪
等待开盘 02-04 09:30:00 美东时间
28.25
-3.270
-10.37%
华盛通- 最 高30.90
- 今 开30.87
- 成交量 2341.07万股
- 最 低 28.19
- 昨 收 31.52
- 总市值 164.70亿
- 52周最高 49.66
- 市盈率 静 877.33
- 换手率 4.02%
- 52周最低 28.1221
- 委 比 91.30%
- 总股本 5.83亿
- 历史最高 69.93
- 量 比 2.39
- 振 幅 8.60%
- 历史最低 11.91
- 每 手 1
- 风险率 4.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Toast Stock Is Falling After PayPal Earnings
Toast shares are sliding Tuesday after PayPal posted weaker-than-expected fourth-quarter results and withdrew its long-term financial targets.
今天 02:08
These Fintech Stocks Could Be Real Winners Amid Trump's Affordability Push, Says Citi
The US financial technology sector could experience a significant upswing as Trump shifts his focus to affordability, according to analysts.
01-23 18:29
Toast, Southern And More On CNBC's 'Final Trades'
Ritholtz Wealth Management CEO Joshua Brown reiterated his buy action on Toast, adding that he likes the price action on Tuesday.
01-21 21:10
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Oppenheimer Maintains Outperform on Toast, Lowers Price Target to $48
Oppenheimer analyst Rayna Kumar maintains Toast (NYSE:TOST) with a Outperform and lowers the price target from $49 to $48.
01-13 01:42
Wolfe Research Downgrades Toast to Peer Perform
Wolfe Research analyst Darrin Peller downgrades Toast (NYSE:TOST) from Outperform to Peer Perform.
01-08 20:52
Dick's Sporting, Intuitive Surgical And A Tech Stock On CNBC's 'Final Trades'
Intuitive Surgical, Dick's Sporting and Toast get shout-outs on the latest edition of CNBC's "Halftime Report Final Trades."
2025-12-19 20:59
SoFi Sinks On Stock Sale — But Palantir, Robinhood Fans Say 'This Is The Before Moment'
SoFi announced a $1.5B public offering & is a potential S&P 500 addition. Investors fear dilution but also see a potential price spike.
2025-12-05 21:19
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
UBS Maintains Buy on Toast, Maintains $50 Price Target
UBS analyst Timothy Chiodo maintains Toast (NYSE:TOST) with a Buy and maintains $50 price target.
2025-12-04 21:23
